I agree. Anyone who can look at the list of catalysts I have pinned here, and think that management needs "to do something," has a serious issue in comprehension skills.
">CAR-T enhancement
>Our merger with Baudax
>The resubmission of our EUA application to the FDA with copy to MHRA in UK
>Tentative regulatory approval for lenz to treat CMML, granted by Australia's Therapeutic Goods Administration
>A finding to continue the study of lenz based on results from the first 20 patients in the aGvHD trial, which could prove to be a cure for certain cancers
>The declaration of a 5:1 forward stock split, depending perhaps on concluding a planned business combination."
And not only could Novavax be considered as a potential partner, but, if "CAR-T enhancement" doesn't encompass Gracell, then they, too, could be distinguished as a possible catalyst.